ADC Therapeutics (ADCT) Non-Current Debt: 2020-2023
Historic Non-Current Debt for ADC Therapeutics (ADCT) over the last 3 years, with Sep 2023 value amounting to $97,707.
- ADC Therapeutics' Non-Current Debt rose 1.01% to $97,707 in Q3 2023 from the same period last year, while for Sep 2023 it was $97,707, marking a year-over-year increase of 1.01%. This contributed to the annual value of $109.7 million for FY2022, which is 25.89% up from last year.
- According to the latest figures from Q3 2023, ADC Therapeutics' Non-Current Debt is $97,707, which was up 0.36% from $97,356 recorded in Q2 2023.
- Over the past 5 years, ADC Therapeutics' Non-Current Debt peaked at $109.7 million during Q4 2022, and registered a low of $32,855 during Q2 2020.
- Moreover, its 3-year median value for Non-Current Debt was $84.6 million (2021), whereas its average is $52.9 million.
- Its Non-Current Debt has fluctuated over the past 5 years, first spiked by 257,541.15% in 2021, then plummeted by 99.89% in 2023.
- ADC Therapeutics' Non-Current Debt (Quarterly) stood at $33,788 in 2020, then surged by 254,064.20% to $87.2 million in 2021, then increased by 25.89% to $109.7 million in 2022, then increased by 1.01% to $97,707 in 2023.
- Its last three reported values are $97,707 in Q3 2023, $97,356 for Q2 2023, and $97,011 during Q1 2023.